Friday, Nov 9, 2018
News Recap:
Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018
Gilead Sciences announced results from studies investigating Epclusa in chronic HCV patients with severe renal impairment undergoing dialysis and Harvoni in pediatric HCV patients aged three to five years. As well there was data from Gilead’s HBV cure development program.
High Prevalence of Cirrhosis in Adults with Chronic...
SAN FRANCISCO--(BUSINESS WIRE)--Nov 9, 2018--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from studies investigating Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) in chronic hepatitis C virus (HCV) infected patients with severe renal impairment undergoing dialysis and Harvoni ® (ledipasvir/sofosbuvir) in pediatric HCV patients aged three to five years, adding to the efficacy and safety profile of sofosbuvir-based regimens across diverse pa
Friday, August 24, 2018
News Recap:
Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.
Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B vi...
Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B virus (HBV)-infection, thus indicating an autoimmune response as possible cause of HCV-infection associated encephalopathy.
Data, however, are sparse. This study aims to prove that HCV patients feature sim
HepCBC has just released new pamphlets
on HBV and HCV in Hindi and Punjabi:
HBV Punjabi
HBV Hindi
HCV Hindi
HCV Punjabi
Be sure to check out all our pamphlets and posters at: http://hepcbc.ca/publications/pamphlets-posters/
Friday, February 9, 2018
News Recap:
Epidemiology:
CTAC Launches Campaign to End Hepatitis C in Canada. The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action.
#EASLmono: Expanding the conversation on hepatitis elimination. The recent European...
Elimination of infection in next 10 years possible through concerted action by policymakers and community leaders.
TORONTO, Feb. 6, 2018 /CNW/ - The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action. CTAC is once again demonstrating its commitment to
According to research in Scientific Reports, the occurrence of age-related cataracts is associated with hepatitis B virus (HBV) and hepatitis C virus C (HCV) infection.
Liver dysfunction is a known significant risk factor for cataract formation, and the liver-damaging effects of HBV and HCV are hypothesised to play a role as well. To test this, associations between hepatitis and cataracts were tested along with any mediation of these associations by the l
Cirrhosis and liver cancer cause 15% of all deaths in Mongolia. Now the government is waking up to the issue – and tackling the hepatitis that triggers it.
Danzan Purev beams as he shows members of a support group photos of his infant nephew on his iPhone. The 68-year-old geologist is charismatic and jokes with the others gathered in the room in Ulan Bator. But his mood changes as he begins to recount his long experience with hepatitis, a disease that has
Friday, November 4, 2017
News Recap:
Access to Treatment
Hepatitis C could be eliminated in Canada, but drug prices, screening barriers stand in the way – Most of the 70 million patients infected with hepatitis C worldwide could be cured for $50 US each Many countries — including Canada — have committed to a global goal of eliminating hepatitis C by 2030. But new data released at the summit in Brazil shows that only nine countries are on track to me...
